Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.70
+0.17003.07%
Post-market: 5.720.0200+0.35%19:30 EST
Volume:4.24M
Turnover:24.12M
Market Cap:1.16B
PE:-10.65
High:5.93
Open:5.58
Low:5.55
Close:5.53
52wk High:7.01
52wk Low:1.89
Shares:203.47M
Float Shares:115.00M
Volume Ratio:3.29
T/O Rate:3.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5350
EPS(LYR):-0.4838
ROE:-78.74%
ROA:-39.67%
PB:12.29
PE(LYR):-11.78

Loading ...

Savara (SVRA) Gets a Buy from Guggenheim

TIPRANKS
·
Yesterday

Stocks to Watch: iPower, Savara

Dow Jones
·
Feb 21

Savara Inc. Publishes Corporate Presentation on Autoimmune PAP and MOLBREEVI (Molgramostim) Program

Reuters
·
Feb 21

FDA accepts Savara’s MOLBREEVI BLA for priority review in autoimmune PAP

Reuters
·
Feb 21

Savara Inc - to Submit Molbreevi MAAS to Ema and Mhra by Q1 2026

THOMSON REUTERS
·
Feb 21

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the Molbreevi* Biologics License Application (Bla) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
Feb 21

Savara Inc - FDA Grants Priority Review, Pdufa Date August 22, 2026

THOMSON REUTERS
·
Feb 21

A Look At Savara (SVRA) Valuation After Recent FDA Progress And Strengthened Outlook

Simply Wall St.
·
Feb 18

Savara Inc. Grants Equity Awards to New Employee

Reuters
·
Feb 14

Savara Inc. nimmt an bevorstehenden Investor Healthcare Conferences teil

Reuters
·
Feb 05

Savara Inc. Highlights Leadership Team and Progress on MOLBREEVI for Autoimmune PAP in New Presentation

Reuters
·
Jan 29

Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI

Reuters
·
Jan 28

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of Molbreevi*

THOMSON REUTERS
·
Jan 27

Assessing Savara (SVRA) Valuation As Legal Scrutiny Over MOLBREEVI Disclosures Intensifies

Simply Wall St.
·
Jan 26

DIARY-India economic, corporate events on January 20

Reuters
·
Jan 20

Savara Grants Stock Options and RSUs to New Employees

Reuters
·
Jan 17

What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders

Simply Wall St.
·
Jan 17

Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential

TIPRANKS
·
Jan 10

Savara Submits MOLBREEVI BLA to FDA for Autoimmune PAP Treatment

Reuters
·
Jan 09

Savara Inc : H.c. Wainwright Raises Target Price to $10

THOMSON REUTERS
·
Dec 23, 2025